Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 364-367

  Alten, R E ^a   Zerbini, C ^b   Jeka, S ^c   Irazoque, F ^d   Khatib, F ^e   Emery, P ^f   Bertasso, A ^g   Rabbia, M ^g   Caulfield, J P ^h  

^a Schlosspark Klinik   (Germany)

^b HOSPITAL HELIÓPOLIS   (Brazil)

^c NZOZ Nasz Lekarz   (Poland)

^d CMN 20 de Noviembre   (United States)

^e Arwyp Medical Suites   (South Africa)

^f CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^g HOFFMANN LA ROCHE INC   (United States)

^h ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; PLACEBO; UNCLASSIFIED DRUG;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SINUSITIS; SKIN DISEASE; THORAX DISEASE; TREATMENT OUTCOME; TREMOR; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749115980     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.104802     Document Type: Article

References (15)

1. Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008;327:610-9.
2. Herlaar E, Brown Z. p38 MARK signaling cascades in inflammatory disease. Mol Med Today 1999;5:439-47.
3. Guan Z, Buckman SY, Pentland AP, et al. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J Biol Chem 1998;273:12901-8.
4. Lee JC, Kassis S, Kumar S, et al. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther 1999;82:389-97.
5. Hale KK, Trollinger D, Rihanek M, et al. Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J Immunol 1999;162:4246-52.
6. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
7. Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54:2745-56.
8. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. Felson DT, Anderson JJ, Boers M, et al. T he American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arth Rheum 1993;36:729-40.
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting, E2A; 27 October 1994. http://www.ich.org/LOB/media/ MEDIA436.pdf (accessed 2 Dec 2009).
11. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study in patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44.
12. Damjanov N, Kauffman R, Spencer-Green GT. Safety and efficacy of VX-702, a p38 MAP kinase inhibitor, in rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl II):125.
13. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34.
14. Laffitte E, Saurat JH. Kinase inhibitor-induced pustules. Dermatology 2005;211:305-6.
15. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20.